Stock Price Forecast

June 1, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Tcr2 Therapeutics Inc chart...

About the Company

at tcr2 therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. we have developed a unique proprietary truc™ platform based on t cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete t cell receptor (tcr). our truc™ variants can reprogram the natural tcr complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. we have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe truc™-t cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic. the company was founded in 2015 by dr. patrick baeuerle and backed with a $44.5m series a financing led by mpm capital and f2 ventures. we have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of kendall square in cambridge, ma.

CEO

Garry Menzel

Exchange

NASDAQ

Website

tcr2.com

$M

Total Revenue

137

Employees

$58M

Market Capitalization

-1.00

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TCRR News

Tcr2 Therapeutics (NASDAQ: TCRR)

11mon ago, source: The Motley Fool

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the ...

Todd Foley's Net Worth

17d ago, source: Benzinga.com

Todd Foley has an estimated net worth of $598 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., iTeos Therapeutics, Inc., TriVascular ...

Ovid Therapeutics Inc OVID

12h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

Kintara Therapeutics Inc KTRA

17h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

ONTX Onconova Therapeutics, Inc.

3d ago, source: Seeking Alpha

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

23d ago, source: Yahoo Finance

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results.

Pliant Therapeutics, Inc.

1mon ago, source: CNN

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...

Intellia Therapeutics, Inc.

2mon ago, source: CNN

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...

Viking Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Plus Therapeutics Inc.

3y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...